leisure time -WSS

leisure time

author：Wikipedia 2025-08-30 19:13:59 - browse：4853

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

WSS

IVF, abortion rights issues kick off Biden’s State of the Union

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Precocious puberty in girls comes with mental health risks

IVF, abortion rights issues kick off Biden’s State of the Union

UnitedHealth quietly bought dozens of outpatient centers

Novo Nordisk obesity pill bests Wegovy in early trial

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

These geoengineering technologies could help combat the climate crisis, scientists say

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Duchenne breakthrough therapy leaves behind pioneering families

Former medical device CEO who sold dummy, plastic parts convicted of fraud

ChatGPT in medicine: STAT answers readers' burning questions

Pfizer's Covid pill remains 89% effective in final analysis, company says

entertainment

Just how do doctors, lawmakers, and the public define abortion?

Connecting traumatic brain injury and domestic violence

The problem with charging patients to message their doctors

Precocious puberty in girls comes with mental health risks

Change Healthcare payments predicted restored March 15

Grail is spending more than ever lobbying Congress

hotspot

explore

leisure time

knowledge